申请人:The Trustees of Columbia University in the City of New York
公开号:US10421720B2
公开(公告)日:2019-09-24
The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatment of diseases characterized by excessive lipofuscin accumulation in the retina.
本发明提供具有以下结构的八氢环戊吡咯化合物:(结构表示)其中psi不存在或存在,存在时为键;R1、R2、R3、R4和R5各自独立地为H、卤素、CF或C1-C4烷基;R6不存在或存在,存在时为H、OH或卤素;A不存在或存在,存在时为C(O)或C(O)NH;B 是取代或未取代的单环、单车、杂单环、杂单车、苄基、CO2H 或 (C1-C4 烷基)-CO2H,其中当 B 是 CO2H 时,则 A 存在且为 C(O);当 psi 存在时,则 R6 不存在,当 psi 不存在时,则 R6 存在,或其药学上可接受的盐,用于治疗以视网膜中脂褐素过度积累为特征的疾病。